Aura Biosciences (AURA) EV to EBITDA (2021 - 2026)
Analysis
Aura Biosciences (AURA) EV to EBITDA (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Aura Biosciences | 711.48 Mn | 643.64 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.87 |
| Mar 31, 2026 | -9.88 |
| Dec 31, 2025 | -10.54 |
| Sep 30, 2025 | -12.24 |
| Jun 30, 2025 | -9.83 |
| Mar 31, 2025 | -8.82 |
| Dec 31, 2024 | -13.64 |
| Sep 30, 2024 | -18.00 |
| Jun 30, 2024 | -15.15 |
| Mar 31, 2024 | -16.24 |
| Dec 31, 2023 | -12.51 |
| Sep 30, 2023 | -14.02 |
| Jun 30, 2023 | -20.84 |
| Mar 31, 2023 | -16.06 |
| Dec 31, 2022 | -10.94 |
| Sep 30, 2022 | -29.24 |
| Jun 30, 2022 | -26.12 |
| Mar 31, 2022 | -41.71 |
| Dec 31, 2021 | 5.28 |